Two-year data showed significant functional improvements in patients treated with delandistrogene moxeparvovec compared to controls, despite initial trial endpoint failure. The treated group exhibited ...

LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S.

Please provide your email address to receive an email when new articles are posted on . Nirsevimab and maternal vaccination produced strong increases in RSV neutralizing antibodies in infants.

Rusfertide effectively maintains hematocrit control and reduces phlebotomy need in PV patients, as shown in the VERIFY study over 52 weeks. The therapy, a hepcidin mimetic peptide, regulates iron ...